Inhibikase Therapeutics

IKT

市值 US$2.3億

WILMINGTON, Del., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 128,000 shares of the Company's common stock to two newly-hired non-executive employees under the Company's 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of September 30, 2026 (the “Effective Date”). The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2026, and highlighted recent developments.

WILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of PAH.

WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that it has sold 25,000,000 shares of the Company's common stock to RA Capital Management through its at-the-market (“ATM”) facility for gross proceeds of $50 million.

WILMINGTON, Del., July 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 981,243 shares of the Company's common stock to seven newly-hired non-executive employees under the Company's 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of June 30, 2026 (the “Effective Date”).

WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended March 31, 2026, and highlighted recent developments.

WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that the first patient has been enrolled in the Company's pivotal Phase 3 study IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH; NCT07365332).

WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 685,718 shares of the Company's common stock to five newly-hired non-executive employees under the Company's 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of March 31, 2026 (the “Effective Date”). The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.68 per share, which is equal to the closing price of the Company's common stock on the Effective Date. The options have a ten year term, with 25% vesting on the first anniversary of the Effective Date and the remaining 75% vesting in 36 equal monthly installments thereafter. The options are subject to the terms and conditions of the Inducement Plan approved by the Company's Board of Directors in March 2026 and the terms and conditions of award agreements covering the grants.

WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the year ended December 31, 2025 and highlighted recent developments.

WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the pricing of its underwritten public offering of 46,091,739 shares of common stock and pre-funded warrants to purchase 22,873,779 shares of common stock. The shares of common stock are being sold at an offering price of $1.45 per share, and the pre-funded warrants are being sold at an offering price of $1.449 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. In addition, Inhibikase has granted the underwriters a 30-day option to purchase up to an additional 10,344,827 shares of its common stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to Inhibikase from this offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding the exercise of any pre-funded warrants. All of the securities being sold in the offering are being offered by Inhibikase. The offering is expected to close on November 24, 2025, subject to the satisfaction of customary closing conditions.